Now, health goes beyond diagnosis; it’s about prevention.
The journey to well-being can be perfected by adding health data collection and intelligent analysis.
Wellysis leads the transformation of healthcare for prevention by adding the power of data-driven insights.
The worldwide leading cause of death every year is related to cardiovascular diseases.
A typical cardiovascular condition, arrhythmia, often occurs without symptoms and requires continuous ECG (electrocardiogram) monitoring due to its intermittence. In so, early detection is a necessity for a more healthier life.
We aim to improve the accessibility of ECG testing, address individual inconveniences, and streamline the testing process, allowing individuals to closely monitor their hearts in everyday life.
#1
Death rate due to cardiovascular diseases
(WHO, 2019)
80%
Sudden cardiac death due to arrhythmia
5x
Risk of Stroke caused by Atrial Fibrillation
2025
2025.04
Participated in HRS 2025 (Heart Rhythm Society)
Participated in ACC 2025 (American College of Cardiology)
2024
2024.10
Presented an AF prediction model based on 72-hour ECG at the 2024 Heart Rhythm Congress (UK, by invitation), published in the European Journal of Arrhythmia & Electrophysiology
Published an atrial fibrillation prediction AI model with Samsung Medical Center in Journal of the American Heart Association (JAHA)
2024.07
Awarded the Grand Prize at the 2024 Healthcare Big Data Utilization Startup Competition
2024.01
S-Patch ExL FDA approved
2023
2023.10
Established Wellysis USA Inc. in Houston, TX
2023.08
S-Patch Ex FDA approved
2023.06
Selected for ‘2023 Global ICT Future Unicorn (ICT GROWTH)’ by the Ministry of Science and ICT
World Athletics X Wellysis Thermoregulation event, Austria
2023.02
Selected for ‘JLABS SFF Program’ by Johnson & Johnson Services, Inc.
2022
2022.11
Exhibited at HLTL 2022, Las Vegas, U.S. (Invited by Samsung Electronics)
2022.09
Introduced S-Patch solution at International First Responder Showcase (Hosted by IFAFRI)
2022.01
Exhibited at CES 2022, Las Vegas, U.S.
2021
2021.07
Established R&D Office in Pangyo, Korea
2021.05
Launched Wellysis Partners Day & Released S-Patch Ex (2nd Generation)
S-Patch EX CE approved
Selected for Korea Medical Device Research & Development Project
(Consortium led by Samsung Seoul Hospital)
2021.04
S-Patch Ex approved by MFDS
2021.02
S-Patch Ex certified GMP
2020
2020.12
Published journals in CSANZ (Cardiac Society of Australia and New Zealand)
2020.10
Signed an exclusive distributor and investment contract with Samjin Pharmaceutical Co., Ltd.
2020.06
Signed the research contract for Covid-19 Wearable project with Stanford University
2020.04
S-Patch Cardio CE approved
2020.02
Awarded for Sydney Landing Pad, Australia
2019
2019.10
Received AI Innovations Award by HIMSS APAC
Published journal in APHRS (Asia Pacific Heart Rhythm Society)
2019.09
S-Patch Cardio approved by MFDS
Selected for TIPS Program by the Ministry of SMEs and Startups
Signed MOU of joint development on Apollo Hospitals India Business
2019.05
Founded Wellysis Corp.
Signed an investment contract with Samsung Venture Investment
2019.04
Spin-off from Samsung SDS Digital Health
